Abcam, ab266471, Human CHCHD3 (MIC19) knockout HEK-293T cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
CHCHD3 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-CHCHD3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MIC19 also known as mitofilin is an integral component of the inner mitochondrial membrane part of the mitochondrial inner membrane organizing system (MINOS). It has a molecular mass of approximately 86 kDa. Expression of MIC19 occurs mainly in tissues with high energy demands including the heart and skeletal muscles. It plays a mechanical role in maintaining the structural integrity of mitochondrial cristae by anchoring specific protein components within the membrane.
Biological function summary
MIC19 contributes to the organization and functional maintenance of mitochondrial architecture by participating in the MINOS complex. This complex regulates the interaction between the inner and outer mitochondrial membranes ensuring efficient mitochondrial dynamics and biogenesis. Furthermore MIC19 supports mitochondrial bioenergetics by stabilizing cristae structures necessary for optimal electron transport chain function.
Pathways
MIC19 integrates into the processes controlling mitochondrial fusion and fission dynamics. It functions within the pathways that are essential for cellular energy metabolism and apoptosis. MIC19 influences these pathways through interactions with proteins such as OPA1 which regulates inner membrane fusion and with components of the electron transport chain. This integrative role highlights MIC19's involvement in maintaining cellular energy homeostasis and programmed cell death.
MIC19 associates with neurodegenerative diseases and cardiomyopathies. Altered expression or mutations in MIC19 can disrupt cristae architecture impairing mitochondrial function and energy production. This disruption relates to the disease processes seen in mitochondrial myopathy where proteins like OPA1 also play a role in mediating mitochondrial dysfunction. The interconnected roles of MIC19 and these associated proteins suggest potential therapeutic targets for intervention in mitochondrial-related conditions.